$Biohaven (BHVN.US)$
looks unstoppable
Kv7
Start q1 ph2/3 in epilepsy
Strat q1 ph2/3 in bipolar disorder
Start q1 ph2 in MDD
Start q2 p2/p3 in ge. epilepsy
They are after $Xenon Pharmaceuticals (XENE.US)$
Ph2 data in OCS Q2
Start h2 ph2 in migrane TRPM3
Start q2 ph2 in MS TYK2
Ph1 data q1 in IgG
ADC Trop2 and more

Gainers:
• $Aura Biosciences (AURA.US)$ +13.9% (reports topline data from study of AU-011)
• $Hyzon Motors (HYZN.US)$ +8.2% (to collaborate with $Schlumberger (SLB.US)$ in decarbonizing oil & gas field operations with high-power fuel cells)
• $Apogee Enterprises (APOG.US)$ +6.3% (In reaction to earnings/guidance)
• $GMS Inc (GMS.US)$ +6% (In reaction to earnings/guidance)
• $Darden Restaurants (DRI.US)$ +4.2% (In reaction to earnings/gui...

Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets amid the broader market strength.
Vaccine stocks continued to experience selling pressure in the week. Data readouts and presentations at conferences also moved stocks in either direction.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) was among the biggest gainers after it reported positive topline results from the Phase 2b study of XEN1101 in adult patients with focal epilepsy. On the other hand, Prelude Therapeutics Incorporated (NASDAQ:PRLD) lost about one-half of its market-cap following its presentations at the AACR-NCI-EORTC conference.
Meanwhile, Allogene Therapeutics, Inc. (NASDAQ:ALLO) lost over 100% after the Food and Drug Administration imposed a clinical hold on its CAR T-cell therapy studies following reporting of a chromosomal abnormality in a treated patient.
ChemoCentryx, Inc. (NASDAQ:CCXI) shares benefitted from a positive FDA decision for its avacopan as a treatment for ANCA-associated vasculitis.
Three healthcare companies debuted on Wall Street, raising a combined $452 million.
$ChemoCentryx (CCXI.US)$ $Allogene Therapeutics (ALLO.US)$ $Xenon Pharmaceuticals (XENE.US)$

UPDATED VERSION PART 1 $XENE — STOCK & OPTION PLAY
NEED IT TO BREAK OVER: $33.15
key indicator for MORE uptrend $33.31
confirmation uptrend - $33.56
mini breakout - $33.74
full breakout - $34
SEMI PARABOLIC - $34.22
stop loss — $31.85
& support - $30.61. $Xenon Pharmaceuticals (XENE.US)$